Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-selenomethylselenocysteine (also known as Se-methyl-L-selenocysteine or MSC) is a naturally occurring organic selenium compound found in Allium and Brassica vegetables, such as garlic and broccoli. It is a highly bioavailable, non-protein-accumulating selenoamino acid that acts as a prodrug. Upon oral administration, it is metabolized by kynurenine aminotransferase 1 (KYAT1) / cysteine-S-conjugate β-lyase to generate methylselenol, a highly active anticancer and antioxidant metabolite. L-selenomethylselenocysteine has been evaluated in clinical trials (Phase I/II) as a chemopreventive agent for prostate and breast cancers, and as a chemosensitizer or protective agent to reduce chemotherapy-induced toxicities (such as mucositis). It is also widely marketed as a dietary supplement for antioxidant and immune support.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-selenomethylselenocysteine.